Indiatimes13d
Vaccine maker Moderna forecasts lower sales next year, shares tumble 17% to near four-year low
Moderna has delayed its break-even goal by two years, pushing it to 2028, due to slower regulatory processes for key products like flu and cancer vaccines. The company expects lower sales in 2025 ...
Wall Street Journal13d
Moderna Cost Cuts Fail to Restore Investor Trust
After raking in a vaccine windfall during the pandemic, Moderna has hemorrhaged money to develop its mRNA technology. (Adam Glanzman/Bloomberg News) Moderna is under pressure to deliver ...
WCVB Channel 5 Boston14d
Moderna plans to slash research and development, focus on commercial business
Moderna, the Massachusetts-based biotech company that rocketed into the global spotlight during the development of its COVID-19 vaccine, announced plans on Thursday to cut costs and refocus on ...
Boston Herald14d
Ticker: Moderna cuts research spending; Mortgage rates inch down
Vaccine developer Moderna said it was cutting research and development spending and pushed back its time frame for breaking even. The company on Thursday also forecast a 2025 revenue range that ...
bnnbloomberg14d
Moderna Plunges as Sales View Disappoints, Research Budget Cut
(Bloomberg) -- Moderna Inc. said it aims to reduce its research and development budget by about 20% over the next three years as it tries to find a path to profitability following disappointing ...
Yahoo Finance14d
Moderna Outlines Post-Covid Roadmap, Cuts Research Budget, Forecasts 2025 Sales Below Expectations
Thursday, Moderna Inc (NASDAQ:MRNA) unveiled key updates at its annual R&D Day, spotlighting its mRNA-based pipeline and revised financial plans. CEO Stéphane Bancel emphasized the company’s ...
ABC News14d
Moderna lays out plan to slice research and development spending
Shares of Moderna tumbled early Thursday after the vaccine developer said it was cutting research and development spending and pushed back its time frame for breaking even Shares of Moderna ...
STAT14d
A new threat to Merck’s blockbuster cancer treatment, Moderna’s cutbacks, and obesity drugs for kids
Who’s the iconoclastic outsider behind Summit’s success? Why can’t Moderna turn a profit? And should we be giving weight loss drugs to kids? We talk about all that and more on this week’s ...
STAT14d
Moderna touts research progress as it cuts R&D spending by $1.1 billion
Moderna said Thursday it would cut its annual spending on research and development by 23%, or $1.1 billion, between 2024 and 2027 in a concession to investors who have viewed the company’s ...
Sportmediaset14d
CONTABILITÀ OPACA, DA LUNEDÌ MANCHESTER CITY A PROCESSO
Inizia lunedì prossimo, 16 settembre, il maxi-procedimento che vede il Manchester City imputato di 115 infrazioni e violazioni del fair play finanziario previsto in Premier League. Il club ...
Invezz14d
Why is Moderna’s stock crashing today? Here’s what we know
Moderna slashes R&D budget by $1.1B, stock plunges 13%. Revenue guidance cut; RSV vaccine market outlook dims. Watch $67 support; a break could lead to further decline. Moderna Inc. (NASDAQ: MRNA ...